A Long-Term Extension Study of Lesinurad in Combination with Febuxostat for Subjects with Gout Completing an Efficacy and Safety Study of Lesinurad and Febuxostat
18 Years - 85 Years
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jan 2017 by Ardea Biosciences, Inc.
Ardea Biosciences, Inc.
No locations available
|Experimental: lesinurad 400 mg + febuxostat 80 mg|
Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 3, dated 07 October 2015.
Tablets, 400 mg once daily (QD)
|Experimental: lesinurad 200 mg + febuxostat 80 mg|
Tablets, 200 mg QD